FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030194121> ?p ?o ?g. }

• W3030194121 endingPage "e15055" @default.
• W3030194121 startingPage "e15055" @default.
• W3030194121 abstract "e15055 Background: There is immune evasion and resistance to checkpoint inhibitors (CPI). Programmed death-ligand 1 (PD-L1) and Tumor mutational burden (TMB) might help us predict response, but we have not yet validated biomarkers that can predict resistance. Mutations (mut) in STK11 can induce epigenetic changes that confer proliferative advantages to cancer cells and preliminary reports have suggested that they can confer resistance to CPI. We investigated the role of STK11 and KRAS mut as markers of poor response to CPI in patients (pts) with non-small cell lung cancer (NSCLC). Methods: Clinical outcomes of 127 pts with stage IIIB-IV NSCLC who were tested for KRAS and STK11 mut and received CPI were evaluated for progression free survival (PFS) and overall survival (OS). For statistical analysis log-rank tests were used to compare OS and PFS, chi-squared tests were used to compare 1-year survivals and proportions among different variables, and Kaplan-Meier survival curves were used to report OS and PFS. Results: Of the 127 pts: 31 had STK11 mut, 14 had STK11+KRAS mut (SKM group), and 10 pts were in the SKMP group (STK11+KRAS mut+PD-L1 (-)). Median age was 65y (27-88y). Males were 54% of the total and 30 pts (24%) were Hispanic (H). STK11 mut patients had an inferior PFS and OS as shown in table. Pts in SKM and SKMP groups had worse outcomes; however, not all the P values were significant. The difference in OS and 1-year OS were very impressive and significant when compared between the SKMP group (4m and 30%) and the wild type group (15m and 73%). There were no significant differences in clinical outcomes for H vs. non-H White pts. Conclusions: The presence of STK11 mut were associated with shorter OS/PFS in NSCLC pts treated with CPIs, proving its utility as a negative predictive marker. This can be enhanced combining STK11 and KRAS mut and possibly adding PD-L1 (-). These findings are consistent with recent studies that have reported STK11 mut as a genomic driver of primary resistance. Due to the small sample size further studies will be needed to validate these findings. [Table: see text]" @default.
• W3030194121 created "2020-06-05" @default.
• W3030194121 creator A5012572593 @default.
• W3030194121 creator A5016124826 @default.
• W3030194121 creator A5037375289 @default.
• W3030194121 creator A5042935034 @default.
• W3030194121 creator A5044984711 @default.
• W3030194121 creator A5049557747 @default.
• W3030194121 creator A5076337832 @default.
• W3030194121 creator A5078167233 @default.
• W3030194121 date "2020-05-20" @default.
• W3030194121 modified "2023-10-16" @default.
• W3030194121 title "Serine/threonine kinase 11 (STK11) mutations and immunotherapy resistance in patients with non-small cell lung cancer." @default.
• W3030194121 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e15055" @default.
• W3030194121 hasPublicationYear "2020" @default.
• W3030194121 type Work @default.
• W3030194121 sameAs 3030194121 @default.
• W3030194121 citedByCount "3" @default.
• W3030194121 countsByYear W30301941212021 @default.
• W3030194121 countsByYear W30301941212022 @default.
• W3030194121 crossrefType "journal-article" @default.
• W3030194121 hasAuthorship W3030194121A5012572593 @default.
• W3030194121 hasAuthorship W3030194121A5016124826 @default.
• W3030194121 hasAuthorship W3030194121A5037375289 @default.
• W3030194121 hasAuthorship W3030194121A5042935034 @default.
• W3030194121 hasAuthorship W3030194121A5044984711 @default.
• W3030194121 hasAuthorship W3030194121A5049557747 @default.
• W3030194121 hasAuthorship W3030194121A5076337832 @default.
• W3030194121 hasAuthorship W3030194121A5078167233 @default.
• W3030194121 hasConcept C121608353 @default.
• W3030194121 hasConcept C126322002 @default.
• W3030194121 hasConcept C143998085 @default.
• W3030194121 hasConcept C207103383 @default.
• W3030194121 hasConcept C2776256026 @default.
• W3030194121 hasConcept C2777701055 @default.
• W3030194121 hasConcept C2777983448 @default.
• W3030194121 hasConcept C2781187634 @default.
• W3030194121 hasConcept C44249647 @default.
• W3030194121 hasConcept C502942594 @default.
• W3030194121 hasConcept C526805850 @default.
• W3030194121 hasConcept C71924100 @default.
• W3030194121 hasConceptScore W3030194121C121608353 @default.
• W3030194121 hasConceptScore W3030194121C126322002 @default.
• W3030194121 hasConceptScore W3030194121C143998085 @default.
• W3030194121 hasConceptScore W3030194121C207103383 @default.
• W3030194121 hasConceptScore W3030194121C2776256026 @default.
• W3030194121 hasConceptScore W3030194121C2777701055 @default.
• W3030194121 hasConceptScore W3030194121C2777983448 @default.
• W3030194121 hasConceptScore W3030194121C2781187634 @default.
• W3030194121 hasConceptScore W3030194121C44249647 @default.
• W3030194121 hasConceptScore W3030194121C502942594 @default.
• W3030194121 hasConceptScore W3030194121C526805850 @default.
• W3030194121 hasConceptScore W3030194121C71924100 @default.
• W3030194121 hasIssue "15_suppl" @default.
• W3030194121 hasLocation W30301941211 @default.
• W3030194121 hasOpenAccess W3030194121 @default.
• W3030194121 hasPrimaryLocation W30301941211 @default.
• W3030194121 hasRelatedWork W2911842472 @default.
• W3030194121 hasRelatedWork W3029218259 @default.
• W3030194121 hasRelatedWork W3031050632 @default.
• W3030194121 hasRelatedWork W4212946229 @default.
• W3030194121 hasRelatedWork W4220771118 @default.
• W3030194121 hasRelatedWork W4308333785 @default.
• W3030194121 hasRelatedWork W4309108445 @default.
• W3030194121 hasRelatedWork W4379280738 @default.
• W3030194121 hasRelatedWork W4384023329 @default.
• W3030194121 hasRelatedWork W4386573160 @default.
• W3030194121 hasVolume "38" @default.
• W3030194121 isParatext "false" @default.
• W3030194121 isRetracted "false" @default.
• W3030194121 magId "3030194121" @default.
• W3030194121 workType "article" @default.